Last edition
News about Global Pharma
Torrent Pharma joins race to acquire stake of Cipla promoters
Torrent Pharma joins race to acquire stake of Cipla promoters
Global Pharma | 24/08/2023 | By Sudeep Soparkar | 843
Graft Polymer inks manufacturing deal with unnamed Israeli pharma firm
Graft Polymer inks manufacturing deal with unnamed Israeli pharma firm
Global Pharma | 24/08/2023 | By Sudeep Soparkar | 721
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development<br />
Global Pharma | 23/08/2023 | By Sudeep Soparkar | 415
Körber and Iocto Announce Partnership for the Integration of Pharmaceutical Equipment with Werum PAS-X MES
Global Pharma | 22/08/2023 | By Sudeep Soparkar | 976
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling
Global Pharma | 21/08/2023 | By Sudeep Soparkar | 815
Antheia Appoints Richard Sherwin as Head of Commercialization
Antheia Appoints Richard Sherwin as Head of Commercialization
Global Pharma | 18/08/2023 | By Sudeep Soparkar | 984
Ascendis Pharma and Phillips-Medisize Receive Third Award for the SKYTROFA Auto-Injector
Ascendis Pharma and Phillips-Medisize Receive Third Award for the SKYTROFA Auto-Injector
Global Pharma | 18/08/2023 | By Sudeep Soparkar | 1412
CPHI Milan to be held at Fiera Milano and Lombardy Pharma Region for 2024
CPHI Milan to be held at Fiera Milano and Lombardy Pharma Region for 2024
Global Pharma | 18/08/2023 | By Sudeep Soparkar | 999
Hikal Limited Shows Resilient Performance Amid Industry Headwinds
Hikal’s Panolisite undergone US FDA audit which was concluded with ‘Zero’ 483 observations. US FDA approval is in line with de-risking strategy for additional API site to service our global customer base.
Global Pharma | 10/08/2023 | By Manvi | 738
Granules India Q1FY24 Revenue from Operations at INR 9855 mn down 3 Percent YoY
ROCE stood at 9.4 percent and net debt stood at INR 8,569 mn
Global Pharma | 10/08/2023 | By Manvi | 760
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy